Boulder, CO – According to filings with the U.S. Securities and Exchange Commission, DMC Biotechnologies is raising $12,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Matthew Lipscomb played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About DMC Biotechnologies

DMC is leading the low cost sustainable transformation of multiple product markets. Our novel, patent-pending technology for rapid engineering of robust microbial hosts enables the production of a broad diversity of specialty chemicals, flavors, fragrances, nutraceuticals, natural products, pharmaceuticals, and APIs.

To learn more about DMC Biotechnologies, visit http://dmcbio.com/

Contact:
Matthew Lipscomb, Chief Executive Officer
720-239-7239
matt@dmcbio.com
https://www.linkedin.com/in/matt-lipscomb-325bba25/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved